Stryker Corp (SYK) company profile
Close on Nov 17, 2026Market cap $120.89BP/E 33.8Yield –
About Stryker
Surgical & Medical Instruments & Apparatus, SIC 3841
Stryker Corporation operates primarily across two operating segments: MedSurg and Neurotechnology, and Orthopaedics and Spine. Its main offerings encompass surgical instruments, endoscopy equipment, medical devices, neurovascular technologies, and neurocranial solutions, as well as knees, hips, spine, and trauma and extremities products. The company also provides customer lease agreements. Stryker serves healthcare organizations, surgeons, hospitals, and clinical specialists.
The company maintains operations and sales activities both domestically within the United States and internationally across non-U.S. locations, including the EMEA region, Ireland, and Germany. The provided annual report excerpts do not disclose the company's specific headquarters location, store counts, or total number of operating facilities.
Summary of the business section of Stryker's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Stryker Corp
- Founded
- 1946
- Headquarters
- Portage, MI
- Address
- 1941 Stryker Way 49002
- Phone
- (269) 385-2600
- Website
- stryker.com
- Employees
- 56,000, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Michigan
- Fiscal year ends
- December 31
- Auditor
- Ernst& Young LLP, Grand Rapids, Michigan
Stock & identifiers
- Ticker
- SYK
- Exchange
- NYSE
- Shares outstanding
- 381M, Sep 30, 2026
- Public float
- $144.31B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, May 17, 2004; 2-for-1, May 15, 2000; 2-for-1, Jun 11, 1996; 2-for-1, Jun 14, 1991; 3-for-2, Jun 20, 1989; 2-for-1, Jun 12, 1987; 3-for-2, Sep 17, 1985; 3-for-2, Nov 15, 1982; 3-for-2, Nov 12, 1980
- SEC CIK
- 310764
- CUSIP
- 863667101
- ISIN
- US8636671013
- FIGI
- BBG000DN7P92
- Share class FIGI
- BBG001S8FR03
- LEI
- 5493002F0SC4JTBU5137
- EIN
- 38-1239739
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kevin Lobo | Chair and CEO, Director | 249,444 |
| Preston Wendell Wells | VP, Chief Financial Officer | 3,971 |
| Emily Kay Baculik | VP, Corporate Controller | 1,554 |
| Dylan Bram Crotty | Group President | 13,711 |
| Debra King | See Remarks | 6,218 |
| M. Kathryn Fink | VP, Chief HR Officer | 13,649 |
| Robert S. Fletcher | VP, Chief Legal Officer | 10,672 |
| Kimberly Ann Montagnino | VP, Chief Comm. Officer | 1,750 |
| Spencer S. Stiles | President and COO | 77,720 |
| William E. Berry Jr | VP, Chief Accounting Officer | 4,041 |
| Viju Menon | Group President | 22,298 |
| James Andrew Pierce | Group President | 91,696 |
| Glenn S. Boehnlein | VP, Chief Financial Officer | 13,195 |
| Yin C. Becker | VP, Chief Corp Affairs Officer | 36,052 |
| Ronda E. Stryker | Director | 13,917,258 |
| Mary K. Brainerd | Director | 7,921 |
| Emmanuel Perez Maceda | Director | 1,322 |
| Rachel Ruggeri | Director | 2,001 |
| Sherilyn S. McCoy | Director | 7,190 |
| Andrew K. Silvernail | Director | 18,465 |
| Giovanni Caforio | Director | 4,530 |
| Rajeev Suri | Director | 7,190 |
| Tatum Lisa M. Skeete | Director | 5,205 |
| Allan C. Golston | Director | 18,500 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $21.40M | $24.78M | $4.64M | $151 | $148 |
| FY2024 | $21.98M | $48.19M | $6.36M | $153 | $129 |
| FY2023 | $20.77M | $42.47M | $6.07M | $126 | $126 |
| FY2022 | $18.56M | $11.42M | $5.25M | $102 | $124 |
| FY2021 | $16.36M | $27.84M | $5.77M | $110 | $126 |
| FY2020 | $13.32M | $24.00M | $4.02M | $118 | $113 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Kevin A. Lobo Chair, Chief Executive Officer and President | $1.49M | $9.76M | $6.92M | $2.25M | $974.91K | $21.40M | -3% |
| Preston W. Wells Vice President, Chief Financial Officer | $653.43K | $1.84M | $1.30M | $514.56K | $103.34K | $4.41M | – |
| Spencer S. Stiles Group President, Orthopaedics | $792.50K | $2.69M | $1.90M | $760.00K | $188.08K | $6.33M | -6% |
| J. Andrew Pierce Group President, MedSurg and Neurotechnology | $792.50K | $2.69M | $1.90M | $754.15K | $188.08K | $6.32M | -6% |
| Viju S. Menon Group President, Global Quality and Operations | $675.00K | $1.65M | $1.17M | $578.00K | $167.48K | $4.24M | -8% |
| Glenn S. Boehnlein Advisor to the Chief Executive Officer and Former Vice President, Chief Financial Officer | $800.00K | – | – | $800.00K | $293.05K | $1.89M | -74% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“On December 31, 2025 we had approximately 56,000 employees”
Corporate history
Events identified from SEC filings
See a number that looks wrong?